TransCode Advances Colorectal Cancer Drug to Phase 2
TransCode Therapeutics, a public biotech company, announced its lead drug TTXMC138 for colorectal cancer has advanced to Phase 2 trials. The drug targets microRNA-10b, a key regulator in metastatic cancer. Phase 1 results showed safety and some efficacy, with 71% of patients experiencing stable disease. The company has raised $100M with no long-term debt. Phase 2 trials focus on colorectal cancer, a high-mortality disease with unmet medical needs.
How this was made

The 30-second read
Why it matters
The article is a forward-looking presentation describing the rationale for targeting microRNA-10b and summarizing prior Phase 0 and Phase 1a safety/tolerability and disease stabilization signals, then stating the program is now in Phase 2 for colorectal cancer with an MRD (ctDNA) approach.
Market read
For traders, the actionable takeaway is limited because the excerpt does not provide a new, time-stamped clinical datapoint, regulatory decision, or financing event; it mainly reiterates prior Phase 0/1a results and states Phase 2 is underway.
What to watch
Key commercial and risk items are missing in the text: trial design details for Phase 2 (primary endpoint, comparator, sample size), manufacturing/delivery platform validation, and whether ctDNA MRD regulatory pathway is expected to be accepted for approval.
Background
TransCode Therapeutics is described as a small biotech developing RNA therapeutics using its TTX delivery platform, with a lead program TTXMC138 targeting colorectal cancer in Phase 2.
Market effects
Highlights continued investor interest in RNA therapeutics and ctDNA MRD-guided oncology strategies, but no cross-company read-across is provided.
No clear regional market linkage beyond general biotech sentiment.
Oncology trial progress is globally relevant, but the article provides no multinational regulatory or market access milestones.
Counterpoint
Phase 2 advancement is promising, but the excerpt does not include Phase 2 enrollment status, endpoints, or any new efficacy datapoint beyond earlier Phase 1a stabilization.
Key entities
- companyTransCode Therapeutics
Subject of the article; lead candidate TTXMC138 is described as advancing in colorectal cancer to Phase 2.
- drug_candidateTTXMC138
Lead compound targeting microRNA-10b, described as in Phase 2 for colorectal cancer.
- technology_platformTTX delivery platform
Proprietary delivery platform described as enabling tumor-agnostic RNA delivery.
- biomarker_targetmicroRNA-10b (miR10b)
Targeted master regulator in metastatic cancer, described as involved in invasion, metastasis, immune evasion, and chemoresistance.
- biomarkerctDNA
Used as the MRD tool to identify high-risk patients post-surgery/chemotherapy.